Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

Elix and University of Vienna Aim to Advance Drug Discovery Using AI

Published

on

Tokyo-based Elix and the University of Vienna signed a joint research agreement aimed at advancing drug discovery using AI technologies.

One of Elix’s business models is the provision of its integrated AI drug discovery platform, Elix Discovery™, developed under the concept of “medicinal chemists can truly use it.” The product comes with an intuitive graphical user interface (GUI) that automatically constructs predictive models for optimal compound profiling. Elix says it also features diverse structure generation capabilities, with a strength in “proposing structures that humans would not conceive.”

By integrating curated structure generation models, including proprietary ones, with predictive models and parameters built into the intuitive GUI, researchers can rapidly and intuitively refine molecular design, notes a company spokesperson, adding that platform supports both ligand-based drug design (LBDD), including pharmacophore modeling and structure-based drug design (SBDD), the latter utilizing docking simulations and other methods, thus enabling exploration across a broader range of approaches.

The second business model focuses on collaborative drug discovery research with pharmaceutical companies, biotech ventures, and academia.

Led by Julien Orts, MSc, PhD, associate professor at the University of Vienna, this research group specializes in NMR spectroscopy techniques to decode the atomic-resolution structures, dynamics, and interactions of biomacromolecules. The lab’s primary focus involves studying protein conformational switches and allostery in signaling, utilizing groundbreaking methodologies they developed such as INPHARMA for validating small-molecule binding modes and NMR for the automated determination of protein-ligand structures.

INPHARMA is a European research and training network focused on improving drug formulation processes, enhancing patient safety, and reducing animal testing in pharmaceutical development.

By applying exact nuclear Overhauser enhancement (eNOE) distance measurements with 0.1 Å accuracy to resolve protein ensembles, scientists in the Orts Lab note that they provide the thermodynamic insights necessary to tackle undruggable targets and advance modern structure-based drug design.

In this joint research project, Elix will collaborate with the Orts research. The parties see this arrangement as merging Elix’s proprietary expertise in chemoinformatics-based approaches and AI-driven molecular generation with the Orts group’s capabilities in structural dynamics and NMR-validated molecular interactions.

The collaboration aims to design and develop novel compounds against traditionally undruggable targets, with a specific focus on intrinsically disordered proteins (IDPs) and proteins implicated in epigenetic signaling and cancer. By integrating AI’s predictive power with experimental atomic-resolution data, the project seeks to bypass the limitations of traditional drug discovery, delivering new therapeutic insights and next-generation candidates for complex diseases, according to the researchers.

We are thrilled to partner with Elix to bridge the gap between advanced structural biology and artificial intelligence. My laboratory has always been driven by the desire to push the boundaries of what NMR can achieve in drug discovery,” says Orts. “By combining our ability to resolve protein dynamics at atomic precision with Elix’s sophisticated AI-driven generation, we can move beyond static structures and begin to target the complex, transient behaviors of proteins that were once considered out of reach. This synergy is exactly what is needed to accelerate the discovery of transformative medicines for the next generation.”

“At Elix, our mission is to rethink drug discovery by bridging cutting-edge AI with experimental innovation,” points out Shinya Yuki, PhD, CEO at Elix. “Collaborating with the [Orts] group allows us to pursue this mission on a global scale, uniting expertise in AI drug discovery with structural biology. We believe this partnership will open new possibilities for targeting diseases that have long remained beyond the reach of traditional drug discovery.”

The post Elix and University of Vienna Aim to Advance Drug Discovery Using AI appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

New webinar: Tackling drug discovery challenges in cancer research

Published

on

Cancer cells

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.

You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.

Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.

Q&A with the speakers follows the presentations.

Register for free now.

The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).

Continue Reading

Uncategorized

Psilocybin proves promising in neuropathic pain mouse study

Published

on

Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.

Continue Reading

Uncategorized

New Spectrometry Technique Could Aid Formulation Development

New Spectrometry Technique Could Aid Formulation Development

Published

on

A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.

According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.

“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”

Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.

The challenge is understanding the link between these things within a heterogeneous sample, he says.

To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.

He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.

Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.

Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.

The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading

Trending

Helixgate Biotech Review July Issue QR CodeScan to Read